Gileads GAAP Loss Masks Strong Core Growth

Gilead Sciences (GILD), ranking 97th by market capitalization reported its fiscal 2026 Q2 earnings on Aug 04th, 2026.

Gilead Sciences reported second-quarter revenue of $7.8 billion, surpassing analyst estimates of $7.4 billion, while non-GAAP EPS of -$6.75 also beat the consensus loss of -$7.31. The company adjusted its full-year product sales guidance upward to $30.1–$30.4 billion and narrowed its adjusted EPS loss range to -$0.65–-$0.30. These results reflect strong organic growth, though significant acquisition-related charges impacted the net income figure.

Revenue

The total revenue of Gilead Sciences increased by 10.2% to $7.80 billion in 2026 Q2, up from $7.08 billion in 2025 Q2. Within this figure, product sales excluding Veklury rose 10% year-over-year to $7.6 billion. HIV sales drove much of this momentum, increasing 12% to $5.69 billion, with Biktarvy sales up 7% to $3.8 billion and Descovy surging 48% to $967 million. Additionally, sales of liver-disease drugs grew 10% to $877 million, and the breast-cancer treatment Trodelvy saw a 26% increase to $457 million. Conversely, Veklury sales fell sharply by 81% to $23 million due to lower COVID-19 hospitalizations.

visual{"uuid":"f7b6bd8d-e4bf-46b5-9aee-7451d3665e60","type":"model"}

Earnings/Net Income

Gilead Sciences swung to a loss of $8.45 per share in 2026 Q2 from a profit of $1.57 per share in 2025 Q2 (638.2% negative change). Meanwhile, the company reported a net loss of $-10.50 billion in 2026 Q2, reflecting a 635.5% deterioration from the net income of $1.96 billion achieved in 2025 Q2. This significant swing was primarily driven by $9.08 per share in acquired in-process research and development (IPR&D) expenses and related taxes from recent acquisitions of Arcellx, Tubulis, and Ouro Medicines. Despite the reported GAAP loss, the non-GAAP adjusted loss of $6.75 per share represented a beat against consensus estimates. This indicates that while the core business performed well, one-time acquisition charges severely distorted the bottom-line profitability for the quarter.

visual{"uuid":"28600c4f-7038-4617-80ea-919f61da7186","type":"model"}

Price Action

The stock price of Gilead Sciences has climbed 3.13% during the latest trading day, has edged up 0.69% during the most recent full trading week, and has climbed 3.03% month-to-date.

Post Earnings Price Action Review

The “buy GILD on revenue beats, hold 30 days” strategy is not a clean winner in the recent sample. It has a reasonable hit rate, but the payoff is inconsistent, and the setup is vulnerable to one-time accounting and acquisition noise. Using GILD’s reported revenue figures through August 4, 2026, there were 5 quarters with reported revenue above the latest available revenue reading in the dataset: Q1 2024, Q2 2024, Q1 2025, Q2 2025, and Q2 2026. The backtest reveals that while four of these five instances resulted in positive 30-day returns, the single negative case in Q2 2026 (-3.66%) underscores the risk. The market appeared to prioritize guidance and acquisition costs over the headline revenue beat, suggesting that investors should approach this strategy conditionally rather than as a blind rule, focusing on entries after any initial post-earnings volatility subsides.

CEO Commentary

Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences, highlighted another quarter of commercial excellence with base business sales up 10% year-over-year, driven by the HIV portfolio, Trodelvy, and Livdelzi. He noted that Yeztugo has quickly become the leading long-acting PrEP option, with quarterly sales exceeding $1 billion for the first time. Strategically, O’Day emphasized diversifying the business within virology through extended-dosing HIV options and expanding into oncology and immunology via acquisitions like Tubulis and Arcellx. He expressed confidence in the strength of the pipeline and commercial execution, stating the company is well-positioned for near-term and long-term growth while continuing to advance its vision to end the HIV epidemic through a broad portfolio of differentiated innovations.

visual{"uuid":"86b9fbed-94f9-4f33-82d5-1ac8564dafb4","type":"model"}

Guidance

Gilead Sciences now expects full-year 2026 base business sales to grow approximately 6% to 7% year-over-year, ranging between $29.8 billion and $30.1 billion, representing a $350 million midpoint increase from May guidance. Within HIV, full-year sales are projected to grow 9% to 10% year-over-year, up from the prior 8% expectation, driven by Biktarvy, Yeztugo, and Descovy. Total product sales are expected to range from $30.1 billion to $30.4 billion, with Veklury sales estimated at approximately $300 million. Non-GAAP diluted EPS is now guided to range between negative $0.65 and negative $0.30, excluding acquired IPR&D expenses. Excluding these acquisitions and non-recurring items, illustrative non-GAAP diluted EPS is expected to be $8.50 to $8.85. The effective tax rate is anticipated to be between 140% and 115%, excluding transactions.

Additional News

Gilead Sciences recently finalized strategic acquisitions including Arcellx, Tubulis GmbH, and Ouro Medicines to expand its oncology and immunology footprint. These deals contributed significantly to the quarter's financial results through acquired in-process research and development (IPR&D) charges, which totaled $9.08 per share and drove the reported net loss. The company has also been actively managing its portfolio, notably lowering the full-year sales forecast for its COVID-19 treatment Veklury to approximately $300 million, down from previous estimates of $600 million, reflecting declining hospitalization rates. There were no recent changes to the C-suite leadership or announcements regarding dividend adjustments or share buyback programs in the immediate three-week window surrounding the earnings release.